Amgen acquires Forbion portfolio company Dezima Pharma
Forbion Capital Partners’ portfolio company, Dezima Pharma, a biotechnology company developing innovative drugs to treat dyslipidemic patients suffering from cardiovascular disease (CVD), is to be acquired by Amgen, Inc. Amgen has agreed to acquire all outstanding shares of Dezima for up to USD1.55 billion from Forbion and other current shareholders,